Auro Labs.

{
  "main_header": {
    "sid": 239365,
    "name": "Auro Labs.",
    "stock_name": "Auro Labs.",
    "full_name": "Auro Laboratories Ltd",
    "name_url": "stocks-analysis/auro-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "271.40",
    "chg": 6.85,
    "chgp": "2.59%",
    "dir": 1,
    "prev_price": "264.55",
    "mcapval": "166.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 530233,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE292C01011",
    "curr_date": "Feb 06",
    "curr_time": "",
    "bse_nse_vol": "15.82 k",
    "exc_status": "Active",
    "traded_date": "Feb 06, 2026",
    "traded_date_str": "2026 02 06",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/auro-labs-239365-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Auro Laboratories Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-auro-laboratories-ltd-fallingrising-3825406",
        "imagepath": "",
        "date": "2026-02-07 00:41:18",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Consistent Outperformance Against Benchmarks</strong></p>\n<p>Auro Laboratories Ltd has demonstrated remarkable returns over various time frames compared to the broader market index, the Sensex. Over the past week, the stock surged by 19.74%, significantly outpacing the Sensex’s modest 1.59% gain. This momentum extends over longer periods as well, with a one-month return of 15.42% against the Sensex’s decline of 1.74%, and a year-to-date gain of 8.80% while the benchmark fell by 1.92%. Even on a one-year basis, the stock’s 16.83% appreciation comfortably exceeds the Sensex’s 7.07% rise.</p>\n<p>More impressively, the stock’s three-year and five-year returns stand at 293.33% and 167.26% respectively, dwarfing the Sensex’s 38.13% and 64.75% gains over the same periods. This consistent outperform..."
      },
      {
        "title": "Are Auro Laboratories Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-auro-laboratories-ltd-latest-results-good-or-bad-3824782",
        "imagepath": "",
        "date": "2026-02-06 19:20:42",
        "description": "Auro Laboratories Ltd's latest financial results for Q2 FY26 reflect a notable operational turnaround, highlighted by a significant quarter-on-quarter revenue growth of 219.13%, rising from ₹2.77 crores in Q1 FY26 to ₹8.84 crores. This surge in revenue indicates a potential resolution of previous supply constraints or the fulfillment of deferred orders. The company also reported a net profit of ₹0.72 crores, reversing a loss from the prior quarter, and achieved an operating margin of 26.70%, a substantial improvement from 0.72% in Q1 FY26.\n\nHowever, despite these positive indicators for the recent quarter, Auro Laboratories faces ongoing structural challenges. The company's five-year sales growth trajectory remains concerning, with an annual decline of 13.87%, and a significant drop in revenue from ₹54.00 crores in FY21 to ₹19.00 crores in FY25. Additionally, the return on equity (ROE) has deteriorated to 2..."
      },
      {
        "title": "Auro Laboratories Q2 FY26: Sharp Revenue Surge Masks Profitability Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/auro-laboratories-q2-fy26-sharp-revenue-surge-masks-profitability-concerns-3823951",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AuroLaboratorie_quaterlyResult_3823951.png",
        "date": "2026-02-05 21:16:13",
        "description": "Auro Laboratories Ltd., a Mumbai-based generic Active Pharmaceutical Ingredients (API) manufacturer specialising in anti-diabetic compounds, reported a dramatic revenue recovery in Q2 FY26, with net sales surging 219.13% quarter-on-quarter to ₹8.84 crores. However, the micro-cap pharmaceutical company's consolidated net profit of ₹0.72 crores, whilst representing a turnaround from the previous quarter's loss of ₹0.11 crores, reflects an unusual tax rate of 58.14% that significantly compressed profitability. Following the results, the stock rallied 4.35% to ₹265.00 on February 5, 2026, though the company's market capitalisation remains modest at ₹156.00 crores."
      },
      {
        "title": "Are Auro Laboratories Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-auro-laboratories-ltd-latest-results-good-or-bad-3822839",
        "imagepath": "",
        "date": "2026-02-05 19:18:54",
        "description": "Auro Laboratories Ltd's latest financial results for Q2 FY26 reflect a significant sequential recovery in both revenue and profitability. The company reported net sales of ₹8.84 crores, marking a substantial quarter-on-quarter growth of 219.13% from ₹2.77 crores in Q1 FY26. This recovery is notable as it follows a challenging period, with the previous quarter showing a decline in revenue.\n\nThe net profit for the same quarter stood at ₹0.72 crores, a notable turnaround from a loss in the prior quarter, indicating a return to profitability. Additionally, the operating margin improved dramatically to 26.70%, up from a mere 0.72% in Q1 FY26, showcasing enhanced operational efficiency as revenues recovered.\n\nHowever, while these results indicate a positive trend in the short term, they must be viewed in the context of the company's broader financial trajectory. The first half of FY26 saw total sales of ₹11.61 cr..."
      },
      {
        "title": "Auro Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/auro-laboratories-ltd-is-rated-sell-3817923",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AuroLaboratorie_mojoScore_3817923.png",
        "date": "2026-02-03 10:12:09",
        "description": "Auro Laboratories Ltd is rated Sell by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 03 February 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "When is the next results date for Auro Laboratories Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-auro-laboratories-ltd-3810220",
        "imagepath": "",
        "date": "2026-01-29 23:15:57",
        "description": "The next results date for Auro Laboratories Ltd is scheduled for 05 February 2026...."
      },
      {
        "title": "Auro Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/auro-laboratories-ltd-is-rated-sell-3801498",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AuroLaboratorie_mojoScore_3801498.png",
        "date": "2026-01-23 10:10:03",
        "description": "Auro Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 23 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Auro Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/auro-laboratories-ltd-is-rated-sell-3789813",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AuroLaboratorie_mojoScore_3789813.png",
        "date": "2026-01-12 10:10:03",
        "description": "Auro Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 January 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Auro Laboratories Ltd Downgraded to Sell Amidst Weak Financials and Technical Setbacks",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/auro-laboratories-ltd-downgraded-to-sell-amidst-weak-financials-and-technical-setbacks-3774157",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AuroLaboratorie_mojoScore_3774157.png",
        "date": "2025-12-30 08:08:56",
        "description": "Auro Laboratories Ltd has been downgraded from a Hold to a Sell rating by MarketsMOJO as of 29 Dec 2025, reflecting a deterioration in its technical outlook alongside persistent financial challenges. The company’s Mojo Score has declined to 41.0, signalling caution for investors amid flat quarterly results, weak debt servicing ability, and a sideways technical trend."
      }
    ],
    "total": 142,
    "sid": "239365",
    "stock_news_url": "https://www.marketsmojo.com/news/auro-laboratories-239365"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "07-Feb-2026",
      "details": "Auro Laboratories Limited has submitted the clippings of Newspaper Publication of the Unaudited Financial Results of the Quarter and Nine Months ended December 31 2025.",
      "source": "BSE"
    },
    {
      "caption": "Financial Results For The Quarter Ended December 31 2025",
      "datetime": "05-Feb-2026",
      "details": "Auro Laboratories Limited has submitted Financial Results for the quarter ended December 31 2025.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting",
      "datetime": "05-Feb-2026",
      "details": "Auro Laboratories Limited has submitted the Financial Results for the Quarter Ended December 31 2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Auro Laboratories Ltd falling/rising?

2026-02-07 00:41:18

Consistent Outperformance Against Benchmarks

Auro Laboratories Ltd has demonstrated remarkable returns over various time frames compared to the broader market index, the Sensex. Over the past week, the stock surged by 19.74%, significantly outpacing the Sensex’s modest 1.59% gain. This momentum extends over longer periods as well, with a one-month return of 15.42% against the Sensex’s decline of 1.74%, and a year-to-date gain of 8.80% while the benchmark fell by 1.92%. Even on a one-year basis, the stock’s 16.83% appreciation comfortably exceeds the Sensex’s 7.07% rise.

More impressively, the stock’s three-year and five-year returns stand at 293.33% and 167.26% respectively, dwarfing the Sensex’s 38.13% and 64.75% gains over the same periods. This consistent outperform...

Read full news article

Are Auro Laboratories Ltd latest results good or bad?

2026-02-06 19:20:42

Auro Laboratories Ltd's latest financial results for Q2 FY26 reflect a notable operational turnaround, highlighted by a significant quarter-on-quarter revenue growth of 219.13%, rising from ₹2.77 crores in Q1 FY26 to ₹8.84 crores. This surge in revenue indicates a potential resolution of previous supply constraints or the fulfillment of deferred orders. The company also reported a net profit of ₹0.72 crores, reversing a loss from the prior quarter, and achieved an operating margin of 26.70%, a substantial improvement from 0.72% in Q1 FY26. However, despite these positive indicators for the recent quarter, Auro Laboratories faces ongoing structural challenges. The company's five-year sales growth trajectory remains concerning, with an annual decline of 13.87%, and a significant drop in revenue from ₹54.00 crores in FY21 to ₹19.00 crores in FY25. Additionally, the return on equity (ROE) has deteriorated to 2...

Read full news article

Auro Laboratories Q2 FY26: Sharp Revenue Surge Masks Profitability Concerns

2026-02-05 21:16:13

Auro Laboratories Ltd., a Mumbai-based generic Active Pharmaceutical Ingredients (API) manufacturer specialising in anti-diabetic compounds, reported a dramatic revenue recovery in Q2 FY26, with net sales surging 219.13% quarter-on-quarter to ₹8.84 crores. However, the micro-cap pharmaceutical company's consolidated net profit of ₹0.72 crores, whilst representing a turnaround from the previous quarter's loss of ₹0.11 crores, reflects an unusual tax rate of 58.14% that significantly compressed profitability. Following the results, the stock rallied 4.35% to ₹265.00 on February 5, 2026, though the company's market capitalisation remains modest at ₹156.00 crores.

Read full news article

Are Auro Laboratories Ltd latest results good or bad?

2026-02-05 19:18:54

Auro Laboratories Ltd's latest financial results for Q2 FY26 reflect a significant sequential recovery in both revenue and profitability. The company reported net sales of ₹8.84 crores, marking a substantial quarter-on-quarter growth of 219.13% from ₹2.77 crores in Q1 FY26. This recovery is notable as it follows a challenging period, with the previous quarter showing a decline in revenue. The net profit for the same quarter stood at ₹0.72 crores, a notable turnaround from a loss in the prior quarter, indicating a return to profitability. Additionally, the operating margin improved dramatically to 26.70%, up from a mere 0.72% in Q1 FY26, showcasing enhanced operational efficiency as revenues recovered. However, while these results indicate a positive trend in the short term, they must be viewed in the context of the company's broader financial trajectory. The first half of FY26 saw total sales of ₹11.61 cr...

Read full news article

Auro Laboratories Ltd is Rated Sell

2026-02-03 10:12:09

Auro Laboratories Ltd is rated Sell by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 03 February 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

When is the next results date for Auro Laboratories Ltd?

2026-01-29 23:15:57

The next results date for Auro Laboratories Ltd is scheduled for 05 February 2026....

Read full news article

Auro Laboratories Ltd is Rated Sell

2026-01-23 10:10:03

Auro Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 23 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Auro Laboratories Ltd is Rated Sell

2026-01-12 10:10:03

Auro Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Auro Laboratories Ltd Downgraded to Sell Amidst Weak Financials and Technical Setbacks

2025-12-30 08:08:56

Auro Laboratories Ltd has been downgraded from a Hold to a Sell rating by MarketsMOJO as of 29 Dec 2025, reflecting a deterioration in its technical outlook alongside persistent financial challenges. The company’s Mojo Score has declined to 41.0, signalling caution for investors amid flat quarterly results, weak debt servicing ability, and a sideways technical trend.

Read full news article

View All News